Cargando…

Microarray data analysis in neoadjuvant biomarker studies in estrogen receptor-positive breast cancer

Microarray data have been widely utilized to discover biomarkers predictive of response to endocrine therapy in estrogen receptor-positive breast cancer. Typically, these data have focused on analyses conducted on the diagnostic specimen. However, dynamic temporal changes in gene expression associat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Jingqin, Ellis, Matthew J
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949646/ https://www.ncbi.nlm.nih.gov/pubmed/20804563 http://dx.doi.org/10.1186/bcr2616

Ejemplares similares

Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?
por: Haricharan, Svasti, et al.
Publicado: (2017)

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
por: Long, Mengping, et al.
Publicado: (2022)

Estrogen receptor-β: why may it influence clinical outcome in estrogen receptor-α positive breast cancer?
por: Shupnik, Margaret A
Publicado: (2007)

PGRMC1: a new biomarker for the estrogen receptor in breast cancer
por: Craven, Rolf J
Publicado: (2008)

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
por: Ellis, Matthew J., et al.
Publicado: (2008)

Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?
por: Lakhani, Sunil R, et al.
Publicado: (2010)

ESR1 alterations and metastasis in estrogen receptor positive breast cancer
por: Lei, Jonathan T., et al.
Publicado: (2019)

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer
por: Marcus, David M., et al.
Publicado: (2013)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status?
por: Harbeck, Nadia
Publicado: (2018)

Measurement of molecular biomarkers that predict the tumor response in estrogen receptor-positive breast cancers after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy
por: Zhu, Teng, et al.
Publicado: (2017)

Estrogen receptor α is involved in the regulation of ITGA8 methylation in estrogen receptor-positive breast cancer
por: Wu, Jingxun, et al.
Publicado: (2020)

Predictors of lymphovascular invasion in estrogen receptor positive/Her-2 negative breast cancer patients treated with neoadjuvant chemotherapy
por: ÇAVDAR, Eyyüp, et al.
Publicado: (2022)

Estrogens and Estrogen Receptor Modulators in Cancer Research and Therapy
por: Treeck, Oliver
Publicado: (2023)

Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers
por: Schleifman, Erica B., et al.
Publicado: (2014)

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
por: Reinert, Tomás, et al.
Publicado: (2020)

Integrative analysis of histopathological images and chromatin accessibility data for estrogen receptor-positive breast cancer
por: Xu, Siwen, et al.
Publicado: (2020)

Expression of Androgen Receptor in Estrogen Receptor–positive Breast Cancer
por: Agrawal, Anil, et al.
Publicado: (2016)

Estrogen Receptor Signaling in Cancer
por: Langdon, Simon P.
Publicado: (2020)

The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer
por: Allred, D Craig, et al.
Publicado: (2004)

Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer
por: Datta, Jharna, et al.
Publicado: (2022)

Mouse models of estrogen receptor-positive breast cancer
por: Mohibi, Shakur, et al.
Publicado: (2011)

Modern reproductive patterns associated with estrogen receptor positive but not negative breast cancer susceptibility
por: Aktipis, C. Athena, et al.
Publicado: (2014)

Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
por: Miller, Christopher A., et al.
Publicado: (2016)

A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer
por: Tan, Weige, et al.
Publicado: (2016)

Estrogen, estrogen receptors, and hepatocellular carcinoma: Are we there yet?
por: Sukocheva, Olga A
Publicado: (2018)

Gene Alterations of Ovarian Cancer Cells Expressing Estrogen Receptors by Estrogen and Bisphenol A Using Microarray Analysis
por: Hwang, Kyung-A, et al.
Publicado: (2011)

Novel Biomarkers to Guide Immunotherapy De-Escalation in the Neoadjuvant Setting in Triple-Negative Breast Cancer
por: Gandhi, Shipra
Publicado: (2023)

Genes Dysregulated to Different Extent or Oppositely in Estrogen Receptor-Positive and Estrogen Receptor-Negative Breast Cancers
por: Zhou, Xianxiao, et al.
Publicado: (2013)

Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers
por: Chiu, Jen-Hwey, et al.
Publicado: (2017)

Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer
por: Tribukait, Bernhard
Publicado: (2021)

Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival
por: Okano, Maiko, et al.
Publicado: (2019)

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer
por: Chan, Melissa, et al.
Publicado: (2015)

Neoadjuvant treatment for male breast cancer
por: Fentiman, Ian Stuart
Publicado: (2023)

Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data
por: Haricharan, Svasti, et al.
Publicado: (2014)

Estrogen receptor positive breast cancers and their association with environmental factors
por: St-Hilaire, Sophie, et al.
Publicado: (2011)

Collaborative Management of Patients With Estrogen Receptor–Positive Breast Cancer
por: Schwartzberg, Lee S., et al.
Publicado: (2017)

Upregulation of HSF1 in estrogen receptor positive breast cancer
por: Gökmen-Polar, Yesim, et al.
Publicado: (2016)

The impact of CBP expression in estrogen receptor-positive breast cancer
por: Ramadan, Wafaa S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k5llr0eboejierjcsjsfb56too